Zobrazeno 1 - 10
of 164
pro vyhledávání: '"Palmar Fibromatosis"'
Autor:
Helen Dakin, Ines Rombach, Melina Dritsaki, Alastair Gray, Catherine Ball, Sarah E. Lamb, Jagdeep Nanchahal
Publikováno v:
Bone & Joint Open, Vol 3, Iss 11, Pp 898-906 (2022)
Aims To estimate the potential cost-effectiveness of adalimumab compared with standard care alone for the treatment of early-stage Dupuytren’s disease (DD) and the value of further research from an NHS perspective. Methods We used data from the Rep
Externí odkaz:
https://doaj.org/article/76adb041d89d4c2e9bbfef39e6f55481
Autor:
Katarzyna Nowak, Gary Wright
Publikováno v:
Rheumatology, Vol 60, Iss 4, Pp 275-280 (2022)
The symptoms of a rheumatic disease may also be a sign of a proliferative process. These include conditions that present with skin and vascular changes such as systemic sclerosis and Raynaud’s phenomenon with peripheral ischaemia and ulceration. Fu
Externí odkaz:
https://doaj.org/article/15f2e83d5cdc4af398db488bdb04a52e
Publikováno v:
Travmatologiâ i Ortopediâ Rossii, Vol 28, Iss 2, Pp 114-123 (2022)
One of the significant problems of surgical treatment of Dupuytrens contracture is skin deficiency after subtotal aponeurectomy. There are many options for skin grafting after subtotal aponeurectomy. However, there is no consensus on surgical approac
Externí odkaz:
https://doaj.org/article/11bbd660f8ca4e3abb0eae6c59f5d9f2
Autor:
Morena Anna Basso, Alessio Bernasconi, Giovanni Balato, Andrea Cozzolino, Giulia Famiglietti, Francesco Smeraglia
Publikováno v:
Acta Ortopédica Brasileira, Vol 31, Iss spe1 (2023)
ABSTRACT Objectives: This study aims to report our experience with Clostridium Histolyticum collagenase (CCH) to support the importance of its clinical use and assess its clinical efficacy, complications, and recurrences. Methods: This prospective ob
Externí odkaz:
https://doaj.org/article/300c56c4bca340368528977d7b3a8012
Publikováno v:
Travmatologiâ i Ortopediâ Rossii, Vol 27, Iss 1, Pp 166-174 (2021)
Background. The data available in the literature on the features of the clinical course and functional prognosis of Dupuytren`s disease in women is contradictory, there are no data on comparative pathomorphological studies of palmar fibromatosis in m
Externí odkaz:
https://doaj.org/article/07e038eb05574e88b17c4279c49a26de
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Pathology and Translational Medicine
Journal of Pathology and Translational Medicine, Vol 55, Iss 4, Pp 265-270 (2021)
Journal of Pathology and Translational Medicine, Vol 55, Iss 4, Pp 265-270 (2021)
Palmar fibromatosis (Dupuytren disease/contracture) is the most common type of fibromatosis, defined as a benign proliferation of fibroblasts and myofibroblasts. The disease process is most common in white, middle-aged and older men occurring at the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aec0965f051d7deae02cbb14f5cf095a
http://europepmc.org/articles/PMC8353138
http://europepmc.org/articles/PMC8353138
Publikováno v:
Hand and Microsurgery, Vol 10, Iss 1, Pp 70-73 (2021)
Dupuytrens disease (DD) is a benign proliferative disease of the hand palm. The fibroproliferative disease can cause palmar nodules and fibrotic bands that lead to flexion contractures in commonly ulnar digits. In this case report, we present the exc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dc820e5fa8bbc503ab932a61a56cb82
http://www.ejmanager.com/fulltextpdf.php?mno=2584
http://www.ejmanager.com/fulltextpdf.php?mno=2584
Publikováno v:
Journal of Life Science and Biomedicine. 11:13-19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84d8ca1e1917cc19a4459660f22d5a67
https://doi.org/10.51145/jlsb.2021.2
https://doi.org/10.51145/jlsb.2021.2